ACCESS Cohorts
Real-time patient cohorts for rapid evidence generation
ACCESS Cohorts are uMed’s prospectively recruited, EMR‑linked registries built to follow real patients over time—not just capture a single snapshot.
Using primary care EHRs, uMed can identify eligible participants at scale, invite them remotely, and enroll patients who consent to long‑term re‑engagement—so clinical and commercial teams stay connected to routine care while allowing unique data collection.
Using primary care EHRs, uMed can identify eligible participants at scale, invite them remotely, and enroll patients who consent to long‑term re‑engagement—so clinical and commercial teams stay connected to routine care while allowing unique data collection.
14,000+
Patients under active data collection
95%
Data completeness
100,000
Patients in active data collection expected in 2026
15m
Patients accessible
What are Cohorts?
A new model for prospective clinical and commercial teams
The evidence compounds longitudinally
Each participant brings deep retrospective clinical history via EHR linkage, and their record continues to refresh as care evolves.
A living clinical timeline
Life science teams can layer prospective data—baseline and ePROs, targeted surveys, at‑home devices, biosamples, and genomics—so the dataset grows in both depth (follow‑up) and breadth (new modalities) without resetting every time a new question appears.
The same cohort is reusable.
You can move faster from question to analysis to insight. Patients can be stratified by real‑world characteristics, run sub‑studies under an umbrella approach, and generate connected evidence across discovery, launch, and lifecycle—without repeated recruitment cycles.
7,320
Patients contacted
From existing uMed network
6,049
Patients responded
in 3 days
20%
GLP-1 users
Prescribed through an e-platform
15 days
to Initial insights
Cohorts in use
GLP-1 Survey
The GLP-1 market represents a rapidly expanding therapeutic frontier, with market forecasts showing it could reach well over $100 billion within the next decade.
We anticipate that analyzing claims data within our AccessCMD cohort will provide valuable insights for pharmaceutical companies seeking to understand real-world GLP-1 use.
As a demonstration of how a ‘SnapACCESS’ study could be conducted, we ran the GLP-1 Experience Survey leveraging our newly expanded cohort.
We collected 6,500 patient responses in 5 days, linking PROs to EHRs to reveal prescribing, persistence and unexpected secondary outcomes for GLP-1 therapy.
We anticipate that analyzing claims data within our AccessCMD cohort will provide valuable insights for pharmaceutical companies seeking to understand real-world GLP-1 use.
As a demonstration of how a ‘SnapACCESS’ study could be conducted, we ran the GLP-1 Experience Survey leveraging our newly expanded cohort.
We collected 6,500 patient responses in 5 days, linking PROs to EHRs to reveal prescribing, persistence and unexpected secondary outcomes for GLP-1 therapy.
Your drugs evidence partner.
Evidence that grows with your product.
One longitudinal, consented patient network. All the evidence your teams need, at every stage, with the same group of patients.
Research & Development
Natural history & patient characterization to inform target populations and endpoint selection.
Rapid feasibility and site selection using real care patterns and diagnosis timelines.
Genotype or biomarker sub-studies integrated into clinical timelines to support translational questions.
Outcome: Better trial design, smarter cohort selection and reduced development risk.
Outcome:
Better trial design, smarter cohort selection and reduced development risk.
Medical Affairs
Patient narratives, validated PROs and clinical context for MSL training, medical education and congress materials.
Post-market safety and pharmacovigilance support with linked EMR signal detection.
Outcome:
Credible clinical narratives and materials grounded in patient experience and real outcomes.
HEOR & Market Access
HTA-ready evidence packages (HTA sections, payer slide packs, BIM/CEA inputs) built from EMR + PRO + utilization data.
Payer Outcomes Packs (utilization, costs, EQ-5D utilities, productivity) to quantify economic impact and inform pricing and reimbursement.
Head-to-head and comparator effectiveness analyses to fortify value dossiers.
Outcome:
Evidence that converts — clear health-economic stories for payers and HTAs.
Commercial
Patient journey segmentation, driver analysis and behaviour-based targeting to shape launch strategy and field tactics.
Rapid qualitative + clinical enrichment (SnapACCESS) to validate messaging, patient preferences and support program design.
Outcome:
Faster, evidence-backed commercial decisions and prioritized customer outreach.
How it works
From identification to insight — Seamlessly connected
Using AI-driven patient matching and automated engagement tools, ACCESS Cohorts identify eligible participants, enroll them remotely, and continuously collect clinically linked data — creating a powerful, living evidence ecosystem.
Identify
EHR-based recruitment & screening: Identify eligible trial patients faster and with better accuracy.
Engage
Remote enrolment to ACCESS Cohort. Data-backed messaging optimization: Highlight what matters most to real patients.
Collect & deliver
Live and ongoing collection of EHR, PROs, wearables and hometesting kits unified into a tailored dataset.
Dive deep
Demonstrate real-world value to payers: Show sustained outcomes like weight loss, A1c control, and reduced complications.
Access Solutions
Two pathways, one cohort network
The ACCESS platform powers two complementary solutions — one for rapid qualitative insight, the other for ongoing, large-scale evidence generation.
Snap ACCESS
Rapid qualitative research with verified patient cohorts. Get actionable insights linked to clinical data in under 4 weeks.
Span ACCESS
Continuous, AI-driven evidence generation across the full product lifecycle.
Harness longitudinal data for large-scale real-world research.
Start building with ACCESS
Join the future of real-world, real-time research
Need help with something else?
Get in Touch
